Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Amr Baber Research INC

Neither a doctor nor a teaching hospital

Research payments

$1,145,824

387 payments

Through program year 2025, Amr Baber Research INC is reported as receiving $1,145,824 in research payments, across 387 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $170,538 137
2024 Research $197,634 115
2023 Research $165,510 39
2022 Research $149,012 38
2021 Research $160,557 33
2020 Research $257,127 21
2019 Research $45,446 4

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $328,170 29 payments
  2. LivaNova USA, Inc. $327,959 232 payments
  3. Janssen Research & Development, LLC $153,684 23 payments
  4. ITI, Inc. $83,668 36 payments
  5. Pfizer Inc. $51,746 22 payments
  6. Biohaven Pharmaceuticals, Inc. $49,211 7 payments
  7. AbbVie, Inc. $45,075 6 payments
  8. H. Lundbeck A S $37,691 12 payments
  9. Neurocrine Biosciences, Inc. $37,236 14 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $31,384 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration: 1-week screening/washout period, 8-week double-blind treatment peri $244,627 18 payments
  2. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) $126,138 27 payments
  3. Recover $86,852 130 payments
  4. A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso $83,790 10 payments
  5. A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression $72,036 20 payments
  6. A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy $69,895 13 payments
  7. Iti-007-602 $63,668 34 payments
  8. A Multicenter 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder $54,359 9 payments
  9. Phase 3 Multicenter Randomized Doubleblind Group Sequential Placebocontrolled Study to Assess Efficacy and Safety of Rimegepant for the Treatment of Migraine With Or Without Aura in Children and Adolescents 6 to 18 Years of Age $51,746 22 payments
  10. Randomized, double-blind, placebo- and active-controlled, parallel group, fixed -dose study in pediatric patients, ages 7-17 years. The study will be approximately 10 weeks in duration 1-week screeningwashout period, 8-week double-blind treatment peri $45,446 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record